[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atheroscleroses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atheroscleroses":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,66,94,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":65},"100635761","clinical-impact-of-using-improve-to-select-patients-for-carotid-revascularisation-100635761",false,"NCT07556887","Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation","Clinical Impact of the Use of IMPROVE for Selection of Patients for Carotid Revascularisation: a Randomized Controlled Multicentre Non-inferiority Trial in Symptomatic Patients With 30-99% Carotid Stenosis","IMPROVE","Inclusion Criteria:\n\n* Mentally competent\n* 18 years or older\n* Recent (\\\u003C30 days) stroke (modified Rankin scale ≤3) or TIA\n* Ipsilateral 30-99% atheromatous stenosis at the carotid bifurcation assessed using non-invasive imaging according to NASCET criteria\n* Life expectancy \\>5 years\n* Patient and stenosis are suitable for carotid revascularisation\n* Patient is agreeable to randomisation and willing to accept either IMPROVE-based or CAU-based selection method for carotid revascularisation\n\nExclusion Criteria:\n\n* Cardiac source of embolism\n* Carotid stenosis caused by non-atherosclerotic disease e.g. dissection, fibromuscular disease or neck radiotherapy.\n* MRI contra-indications\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},613,"ESTIMATED","INTERVENTIONAL",[24],"NA","Narrowing of the carotid artery due to atherosclerosis with an unstable plaque can cause a stroke. Patients with carotid artery disease who have had a TIA or minor stroke and are at high risk of another stroke are often treated with surgery or stenting to remove the plaque. For lower-risk patients, medication alone is the better option, as surgery also carries risks. A new decision method, based on MRI detection of unstable plaques (IMPROVE), can better assess stroke risk and help determine which patients do or do not need surgery. We are investigating whether this method is at least as effective as the standard approach, which mainly considers the degree of narrowing. We expect that this new method will help reduce strokes and lower healthcare costs.\n\nPatients will be followed for several years to compare which method is better for health and costs.",[27,28,29,30,31,32,33,34,35,36],"Carotid Artery Stenosis Symptomatic","Ischemic Cerebral Infarction","Stroke Ischemic","Atheroscleroses","Stroke (CVA) or TIA","Stroke","Intraplaque Hemorrhage","TIA (Transient Ischemic Attack)","Atherosclerosis Cerebral Infarction","Carotid Arteriosclerosis",[38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Carotid Artery Stenosis","Transient Ischemic Attack","Ischemic Stroke","Atherosclerosis","Plaque Rupture","Revascularisation","Carotid Endarterectomy","Carotid Artery Stenting","Magnetic Resonance Imaging","Stroke Risk Prediction","Intraplaque hemorrhage","Clinical Decision Support","Randomized Controlled Mulitcentre Trial","Cost-Effectiveness Analysis","Optimal Medical Therapy","RECRUITING","2026-05-12",{"date":56,"type":57},"2026-05-15","ACTUAL",{"date":59,"type":57},"2026-03-31",{"date":61,"type":21},"2031-08-31",{"name":63,"class":64},"Maastricht University Medical Center","OTHER",10,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":93},"100630894","phase-1-a-study-on-yiyang-huoluo-decoction-in-the-treatment-of-coronary-heart-disease-100630894","NCT07493603","A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease","Clinical and Basic Research on the Treatment of Senile Atherosclerosis and Coronary Heart Disease With Yiyang Huoluo Decoction","Inclusion Criteria:\n\nAll of the following conditions must be met simultaneously for enrollment:\n\n* ① Meet the diagnostic criteria for stable angina pectoris;\n* ② Classified as Grade I to III according to the Canadian Cardiovascular Society (CCS) Angina Grading Scale;\n* ③ Meet the diagnostic criteria for chest discomfort syndrome due to yang qi deficiency and decline (a traditional Chinese medicine pattern differentiation);\n* ④ Aged between 50 and 75 years old;\n* ⑤ Received drug-eluting stent implantation due to severe vascular stenosis (single artery ≥75%， or LM ≥50%) detected by coronary angiography;\n* ⑥ Able to actively comply with medical instructions and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following conditions:\n\n* ① Diagnosed with acute coronary syndrome (including acute ST-segment elevation myocardial infarction, acute non-ST-segment elevation myocardial infarction, and unstable angina pectoris) after relevant examinations;\n* ② Suffer from chest pain caused by non-cardiac diseases other than stable angina pectoris; or have complicated severe hypertension (systolic blood pressure ≥ 180mmHg and\u002For diastolic blood pressure ≥ 110mmHg), severe cardiopulmonary insufficiency, or malignant tumor;\n* ③ Have severe endocrine, hematological or rheumatic immune system diseases, severe hepatic and renal dysfunction, active gastrointestinal bleeding, or mental illness;\n* ④ Have an allergic constitution or a history of allergic reactions to traditional Chinese medicine;\n* ⑤ Have incomplete major baseline data that may affect the trial results, or have participated in other clinical trials recently.","50 Years","75 Years",{"count":76,"type":21},30,[78,79],"PHASE1","PHASE2","The goal of this clinical trial is to learn if Yiyang Huoluo Decoction (a custom Chinese herbal medicine) works safely and effectively to treat coronary heart disease with atherosclerosis in older adults. It also aims to find out how this herbal treatment may affect blood vessel health and repair at a cellular level.\n\nThe main questions it aims to answer are:\n\n* Does adding Yiyang Huoluo Decoction to standard Western medical care improve symptoms and heart-related health in older adults with coronary heart disease and atherosclerosis?\n* Is Yiyang Huoluo Decoction safe for older adults to take alongside their regular heart medications?\n* How does this herbal treatment affect the damaged blood vessels in study participants?\n\nResearchers will compare two groups of participants to see if the combined treatment works better than standard care alone.\n\nWho can take part: Older adults diagnosed with coronary heart disease and atherosclerosis who meet the study's health and eligibility rules.\n\nWhat participants will do:\n\n* Be split randomly into two groups of 15 people each: one group gets standard Western heart medicine only, and the other gets standard Western heart medicine plus Yiyang Huoluo Decoction (herbal granules)\n* Complete the 12-week decoction treatment plan as directed by the research team\n* Attend scheduled study visits for health checks, blood tests, heart and blood vessel scans (such as carotid ultrasound and coronary CTA), and symptom reviews\n* Provide two small blood samples for research testing (samples will be destroyed after study testing is finished)\n* Report any side effects, discomfort, or changes in health to the research team right away\n\nAll personal health information collected for this study will be kept private and confidential. Participation is completely voluntary, and participants may quit the study at any time for any reason without losing access to regular medical care.",[82,83,30],"Coronary Heart Disease","Coronary Artery Disease","2026-03-23",{"date":86,"type":57},"2026-03-25",{"date":88,"type":57},"2026-01-16",{"date":90,"type":21},"2028-06-30",{"name":92,"class":64},"Xia Liang",1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":114,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":93},"100628386","phase-2-trial-of-statin-therapy-effect-on-androgen-status-and-erectile-function-in-men-100628386","NCT07460960","TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men","A Randomized Controlled Trial of Statin Therapy Effect on Androgen Status and Erectile Function in Men With High and Very High Cardiovascular Risk","Inclusion Criteria:\n\n* male patients aged 40-65 years, sexually active\n* high and very high risk of cardiovascular events (The Systematic Coronary Risk Evaluation 2 (SCORE2))\n* absence of previous statin therapy for 3 months\n* there are no known cardiovascular diseases requiring the appointment of statins in high doses from the start of treatment\n* the invariance of concomitant therapy for 3 months, if the patient needs it.\n\nExclusion Criteria:\n\n* known statin intolerance\n* known hypogonadism\n* persistent forms of atrial fibrillation\n* active malignant neoplasm requiring treatment at the time of screening\n* known chronic inflammatory diseases (rheumatoid arthritis, systemic connective tissue diseases, metabolically associated fatty liver disease, etc.)\n* impaired renal function (estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m2) and liver (transaminase levels more than 3 times reference values, bilirubin levels more than 2 times reference values)\n* chronic heart failure\n* a well-known diagnosis of mental illness\n* alcoholism and drug addiction\n* glucocorticoid therapy and regular therapy with nonsteroidal anti-inflammatory drugs (80% of the time for 3 months before switching on)\n* participation in any other clinical trial during this trial, including participation in the trial for 30 days prior to providing informed consent\n* the patient's inability to understand the essence of the study and consent to participate in it","MALE","40 Years","65 Years",{"count":105,"type":21},150,[79],"Aim. To study the effect of different intensities of statin therapy on androgen status and erectile function in men aged 40-65 years with high and very high cardiovascular risk. Additionally, to assess the association between sex hormone levels, erectile function parameters, and traditional cardiovascular risk factors, arterial stiffness, and endothelial function in this patient category.\n\nMaterial and methods. It is planned to conduct a prospective randomized controlled trial, including 150 male patients aged 40-65 years, undergoing routine preventive examinations in the clinic of Moscow State University, having a high and very high risk of cardiovascular diseases and meeting the inclusion criteria. Group Pit (n=75) will receive pitavastatin at a starting dose of 1 mg\u002Fday. Group Ros (n=75) will receive rosuvastatin 20 mg\u002Fday. After 3 months, the biochemical parameters will be monitored, and dose titration of pitavastatin to 2-4 mg\u002Fday and\u002For rosuvastatin to 40 mg\u002Fday will be performed if necessary. Patient recruitment to the study will occur over 9 months at a single research center. Patients will be monitored with an objective assessment of erectile function parameters, blood analysis (including androgen status), central arteries stiffness, and endothelial function for 6 months from the moment of activation. Follow-up visits are scheduled at 1, 3 and 6 months.\n\nResults. The expected result of testing the research hypothesis is that statin therapy will not have a negative effect on androgen status and erectile function in men. Intensive statin therapy will have a greater positive effect on endothelial function, which may lead to an improvement in men's erectile function.\n\nConclusion. The study was planned under the assumption that statin therapy would not have a negative effect on androgen status and erectile function in men aged 40-65 years. It is also suggested that the positive effect of statins on endothelial function and vascular stiffness may lead to an improvement in erectile function among men with high and very high cardiovascular risk. If the hypothesis is confirmed, the results obtained will help improve statin treatment adherence in male patients and, as a result, increase the effectiveness of prevention of cardiovascular events.",[109,30,110,111,112,113],"Erectile Dysfunction Due to Arterial Disease","Erectile Disfunction","Endothelial Dysfunction","Androgen Profile","Testosterone",[115,116,117,118,119,120,121,122,123],"cardiovascular diseases","erectile dysfunction","androgen status","atherosclerosis","statins","statin therapy","coronary artery disease","endothelial dysfunction","testosterone","2026-03-12",{"date":126,"type":57},"2026-03-16",{"date":128,"type":57},"2026-03-05",{"date":130,"type":21},"2027-12",{"name":132,"class":64},"Lomonosov Moscow State University Medical Research and Educational Center",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":151,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":93},"100601244","drug-eluting-balloon-treatment-vs-guideline-directed-medical-therapy-for-the-treatment-of-lipid-rich-plaques-100601244","NCT07107971","Drug-Eluting Balloon Treatment vs. Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques","Drug-Eluting Balloon Treatment Versus Guideline-Directed Medical Therapy for the Treatment of Lipid-Rich Plaques: A Randomized Controlled Trial","DELETE-LRP","Inclusion Criteria:\n\n* Presenting with acute coronary syndrome (ACS);\n* Successful PCI of a native coronary artery or major side branch;\n* At least 2 native coronary arteries are accessible for invasive coronary imaging; i.e. not totally occluded and \\>2 mm and \\\u003C6 mm reference vessel diameter.\n\nExclusion Criteria:\n\n* Hemodynamically unstable (presence of cardiogenic shock, need for intubation, need for inotropes);\n* Known hypersensitivity to paclitaxel;\n* Procedural complications of the index PCI;\n* Known renal insufficiency, i.e. eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2;\n* Hypersensitivity or allergy to contrast with inability to administer steroid and antihistamine premedication;\n* Presence of a comorbid condition with a life expectancy of less than one year;\n* Body weight \\>250 kg;\n* Subject belonging to a vulnerable population (per investigator's judgment, e.g., subordinate hospital staff) or is unable to read or write.",{"count":142,"type":21},400,[24],"The goal of this clinical trial is to find out whether treating vulnerable plaques in the coronary arteries with a drug-coated balloon can make them less dangerous than using standard medication alone. The study includes adults with acute coronary syndrome (a type of heart problem caused by reduced blood flow in the coronary arteries).\n\nThe main questions the study aims to answer are:\n\n* Does the drug-coated balloon reduce the amount of fat inside the plaque more than medication alone?\n* Is this treatment safe for patients?\n\nParticipants will:\n\n* Undergo imaging of their coronary arteries during their planned heart procedure (PCI)\n* Be randomly assigned to receive either a drug-coated balloon treatment or no extra treatment\n* Undergo a heart scan (CT scan of the coronary arteries) within 2 weeks and again around 9 months after the procedure.\n* Undergo a second heart catherization 9 months later to examine changes in the plaque.",[83,30,146,147,148,149,150],"Cardiovascular Disease","Vulnerable Coronary Plaques","Vulnerable Plaque","Lipid-Rich Atherosclerosis of Coronary Artery","Acute Coronary Syndromes (ACS)",[152,153,154,155,156,157,158,159,160],"Lipid-rich plaque","Vulnerable plaque","Near-infrared spectroscopy","Drug-coated balloon","Drug-eluting balloon","Paclitaxel-eluting balloon","Intravascular Ultrasound","Coronary computed tomography angiography","AI-QCT","2026-01-14",{"date":163,"type":57},"2026-01-15",{"date":165,"type":57},"2025-11-04",{"date":167,"type":21},"2033-01",{"name":169,"class":64},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]